Department of Cardiovascular Medicine, Ningbo Hosptial of Zhejiang University, Ningbo First Hospital, Ningbo, Zhejiang Province, 315010, China.
Chin J Integr Med. 2019 May;25(5):360-365. doi: 10.1007/s11655-018-2559-4. Epub 2018 Jun 18.
To observe the immediate effect and safety of Shexiang Tongxin dropping pills (, STDP) on patients with coronary slow flow (CSF), and furthermore, to explore new evidence for the use of Chinese medicine in treating ischemic chest pain.
Coronary angiography (CAG) with corrected thrombolysis in myocardial infarction (TIMI) frame count (CTFC) was applied (collected at 30 frames/s). The treatment group included 22 CSF patients, while the control group included 22 individuals with normal coronary flow. CSF patients were given 4 STDP through sublingual administration, and CAG was performed 5 min after the medication. The immediate blood flow frame count, blood pressure, and heart rate of patients before and after the use of STDP were compared. The liver and kidney functions of patients were examined before and after treatments.
There was a significant difference in CTFC between groups (P<0.05). The average CTFC values of the vessels with slow blood flow in CSF patients were, respectively, 49.98 ± 10.01 and 40.42 ± 11.33 before and after the treatment with STDP, a 19.13% improvement. The CTFC values (frame/s) measured before and after treatment at the left anterior descending coronary artery, left circumflex artery, and right coronary artery were, respectively, 48.00 ± 13.32 and 41.80 ± 15.38, 59.00 ± 4.69 and 50.00 ± 9.04, and 51.90 ± 8.40 and 40.09 ± 10.46, giving 12.92%, 15.25%, and 22.76% improvements, respectively. The CTFC values of vessels with slow flow before treatment were significantly decreased after treatment (P<0.05). There were no apparent changes in the heart rate, blood pressure, or liver or kidney function of CSF patients after treatment with STDP (all P>0.05).
The immediate effect of STDP in treating CSF patients was apparent. This medication could significantly improve coronary flow without affecting blood pressure or heart rate. Our findings support the potential of Chinese medicine to treat ischemic chest pain.
观察麝香通心滴丸对冠状动脉慢血流(CSF)患者的即刻疗效和安全性,为中药治疗缺血性胸痛提供新依据。
采用经校正的心肌梗死溶栓治疗(TIMI)帧数(CTFC)行冠状动脉造影(CAG)(以 30 帧/s 采集)。将 22 例 CSF 患者纳入治疗组,将 22 例冠状动脉血流正常者纳入对照组。CSF 患者舌下含服 4 粒麝香通心滴丸,用药后 5 min 内行 CAG。比较患者用药前后即刻血流帧数、血压和心率,观察患者用药前后肝肾功能变化。
组间 CTFC 比较差异有统计学意义(P<0.05)。CSF 患者慢血流血管治疗前后 CTFC 平均值分别为用药前 49.98±10.01 帧/s、用药后 40.42±11.33 帧/s,改善率为 19.13%。治疗前后左前降支、左旋支和右冠状动脉 CTFC 值(帧/s)分别为 48.00±13.32 帧/s、41.80±15.38 帧/s,59.00±4.69 帧/s、50.00±9.04 帧/s,51.90±8.40 帧/s、40.09±10.46 帧/s,改善率分别为 12.92%、15.25%、22.76%。治疗后 CSF 患者慢血流血管 CTFC 值较治疗前明显降低(P<0.05)。治疗后,患者心率、血压及肝肾功能均无明显变化(均 P>0.05)。
麝香通心滴丸治疗 CSF 患者即刻疗效显著,可明显改善冠状动脉血流,不影响血压和心率,为中药治疗缺血性胸痛提供了一定依据。